Skip to main content

Table 1 Baseline demographics and outcomes in the groups receiving noble metal coated catheter or uncoated control catheter

From: Foley catheter with noble metal alloy coating for preventing catheter-associated urinary tract infections: a large, multi-center clinical trial

  BIP Foley
n = 750
Control
n = 250
p-value Relative reduction (RR) (%)
Demographics and comorbidities
Age, mean (SD) 48 (15) 47 (15) 0.0908 NA
Weight, mean (SD) 65 (34) 69 (58) 0.27 NA
Height, mean (SD) 161 (11) 162 (9) 0.39 NA
Sex, female, n (%) 235 (31) 101 (40) 0.0106 NA
Diabetes mellitus 46 (6.1) 19 (7.6) 0.4 NA
Cancer 5 (0.7) 5 (2) 0.07 NA
Distribution of patients at each site and ward type
Site 1 General surgery and ICU 102 (14) 34 (14) NA NA
Site 2 Urology 6 (1) 2 (1) NA NA
Site 3 Urology 96 (13) 32 (13) NA NA
Site 4 Urology 228 (30) 76 (30) NA NA
Site 5 General surgery 234 (31) 78 (31) NA NA
Site 6 Urology 84 (11) 28 (11) NA NA
Total General surgery and ICU 336 (45) 112 (45) NA NA
Total Urology 414 (55) 138 (55) NA NA
CAUTI
CAUTI incidences (%) TOTAL 52 (6.9) 53 (21.2)  < 0.001 67%
CAUTI/1000 catheter days TOTAL 6.5 (52/(7987 * 10−3)) 20.8 (53/(2551 days * 10−3))  < 0.001 69%
General surgery and ICU (site 1 and 5)
CAUTI/1000 catheter days
12.3 (32/(2612 * 10−3)) 47.9 (37/(773 * 10−3))  < 0.001 70%
Urology (site 2–4, 6)
CAUTI/1000 catheter days
3.7 (20/5375 * 10−3)) 9.0 (16/(1778 * 10−3)) 0.006 58%
Bacteriuria
Positive growth at inclusion TOTAL n (%) 30 (4) 16 (6.4) 0.11 NA
Positive growth TOTAL n (%) 209 (28) 161 (64)  < 0.001 57%
Positive growth, ≥ 105 CFU/ml n (%) 89 (11.9) 67 (26.8)  < 0.001 56%
Positive growth, < 105 ≥ 103, CFU/ml n (%) 66 (8.8) 53 (21.2)  < 0.001 59%
Antibiotics, catheterization days, hospital
Antibiotics prophylaxis*, days/antibiotic treated study patient 8.2 8.5 0.54 No significant difference
Antibiotics prophylaxis, days/all study patients 4.7 5.0 0.47 No significant difference
Duration of catheterization, days 11.1 10.9 0.79 No significant difference
Duration of hospital admission, days 6.5 6.3 0.59 No significant difference
Adverse events
Total number of AE (%) 162 (21.6%) 121 (48.4%)  < 0.001 55%
Total patients with at least one AE n, 112 (14.9%) 80 (32.0%)  < 0.001 53%
  1. *Antibiotics were received for other reasons than catheterization